Carcinoma: Types, Treatment & What It Is

What Is Carcinoma?

Carcinoma is a cancer that begins in epithelial cells, the cells that cover body surfaces and line many internal organs and glands.

Because epithelial tissue is found throughout the body, carcinomas can develop in many different locations. Cancers beginning in the breast, lung, colon, prostate, pancreas, skin and several other organs are frequently carcinomas, although the precise histologic subtype differs.

Carcinoma is therefore not the name of one single disease. It describes the type of cell from which a cancer originated. The organ where the tumor began and the microscopic characteristics of its cells are then used to create a more specific diagnosis.

A diagnosis might therefore be described as lung adenocarcinoma, invasive ductal carcinoma of the breast, squamous cell carcinoma of the skin or urothelial carcinoma of the bladder. Each belongs to the broader carcinoma category but represents a different disease with its own treatment considerations.

What Are the Main Types of Carcinoma?

The main carcinoma types are classified according to the epithelial cells from which the tumor develops.

Adenocarcinoma begins in glandular epithelial cells that produce fluids or mucus. Many cancers of the breast, colon, prostate, pancreas and lung fall into this category.

Squamous cell carcinoma develops from squamous epithelial cells. These flat cells occur in the skin and also line parts of the respiratory, digestive and urinary systems. Squamous cell carcinomas can therefore develop in areas such as the skin, lung, head and neck, cervix, esophagus and anus.

Basal cell carcinoma begins in basal cells in the lower portion of the epidermis. It is a common form of skin cancer and behaves differently from carcinomas arising inside internal organs.

Urothelial carcinoma, historically called transitional cell carcinoma, arises from the specialized lining of the urinary tract. It most commonly affects the bladder but can also originate elsewhere in the urinary collecting system.

The specific cell type matters because cancers originating in different epithelial cells can have different biological behavior, treatment options and prognosis.

What Is Adenocarcinoma?

Adenocarcinoma is a carcinoma that develops from glandular epithelial cells or cells with gland-like characteristics.

These cells are present in organs that produce mucus, digestive fluids, hormones or other secretions. Adenocarcinoma is therefore found in several different organs rather than representing one organ-specific cancer.

A colon adenocarcinoma and a lung adenocarcinoma share a broad histologic category, but they are treated as different cancers because they originated in different organs and have different molecular characteristics.

The word adenocarcinoma alone is therefore incomplete as a diagnosis. The primary site, stage and increasingly the tumor's biomarker profile are needed to understand how the disease should be managed.

What Is Squamous Cell Carcinoma?

Squamous cell carcinoma is a cancer that develops from flat epithelial cells known as squamous cells.

These cells are found near the surface of the skin but also line several internal structures. For this reason, squamous cell carcinoma can arise in many parts of the body.

A squamous cell carcinoma of the skin, for example, is not the same disease as squamous cell carcinoma of the lung or esophagus.

The location where the tumor originated strongly influences treatment. A small localized skin lesion may be treated primarily with local surgery, while a squamous carcinoma originating in an internal organ may require surgery, radiation therapy, systemic medication or a combination.

Histology identifies the cell type, but the organ of origin remains essential to the final diagnosis.

What Is Basal Cell Carcinoma?

Basal cell carcinoma is a skin cancer that begins in basal cells located in the lower part of the epidermis.

It usually behaves differently from many internal carcinomas. Basal cell carcinoma commonly grows locally and is much less likely to spread to distant organs than many other cancers.

That does not mean it should be ignored. Untreated tumors can enlarge and damage nearby skin, cartilage, bone or other structures depending on their location.

Treatment is usually selected according to tumor size, location, recurrence risk and patient characteristics. Surgery is common, although other local approaches may be considered for selected lesions.

The term carcinoma therefore covers cancers with very different clinical behavior, and basal cell carcinoma is a good example of why the word alone does not determine prognosis.

What Is Urothelial Carcinoma?

Urothelial carcinoma is a cancer arising from the urothelium, the specialized epithelial lining of the urinary tract.

It most frequently develops in the bladder but can also arise in the renal pelvis, ureters and other portions of the urinary system.

Older medical records may call it transitional cell carcinoma.

Bladder urothelial carcinoma is further classified according to whether it remains within superficial layers or has invaded the bladder muscle. This distinction strongly influences treatment.

Some tumors can be managed with procedures performed through the bladder and medicines delivered directly into the bladder. Muscle-invasive or metastatic disease often requires more extensive local and systemic therapy.

The exact pathology therefore matters much more than the general carcinoma label.

What Does Carcinoma in Situ Mean?

Carcinoma in situ means abnormal epithelial cells have the microscopic characteristics of cancer but have not invaded through the tissue boundary where they originated.

The phrase in situ means in its original place.

This differs from invasive carcinoma, in which malignant cells have crossed the basement membrane and entered surrounding tissue.

Carcinoma in situ can be clinically important because some lesions have the potential to progress to invasive cancer if left untreated. The likelihood of progression and appropriate management vary considerably depending on the organ and specific diagnosis.

It should also not automatically be interpreted as metastatic or advanced cancer. In situ disease is, by definition, non-invasive at the location being examined.

Understanding this distinction can prevent considerable confusion when reading pathology reports.

What Is Invasive Carcinoma?

Invasive carcinoma is a carcinoma that has grown beyond the epithelial layer where it began and entered nearby tissue.

Invasion is different from metastasis.

A tumor can be invasive while still remaining localized to its original organ. Metastatic cancer means malignant cells have spread to distant tissues or organs.

This distinction matters because the word invasive can sound as if cancer has already spread throughout the body, which is not necessarily the case.

Pathology determines whether invasion has occurred. Imaging, lymph node assessment and other staging tests then help establish how far the disease has actually extended.

What Is the Difference Between Carcinoma and Sarcoma?

Carcinoma begins in epithelial tissue, while sarcoma begins in connective or supporting tissues such as bone, muscle, fat, cartilage or blood vessels.

They are both malignant cancers, but they arise from different cell families.

This distinction has practical consequences because carcinoma and sarcoma are classified and treated differently. A cancer growing inside an organ is not automatically a carcinoma. Some organs can develop tumors arising from connective tissue, lymphatic cells, neuroendocrine cells or other cell types.

Other major cancer categories include leukemia, which begins in blood-forming tissues, and lymphoma, which arises from immune-system cells.

The pathology diagnosis therefore provides information that anatomical location alone cannot.

How Is Carcinoma Diagnosed?

Carcinoma is usually confirmed by examining cells or tissue obtained through biopsy or surgery.

Imaging can identify suspicious lesions and help determine where a tumor is located, but it usually cannot establish the precise histologic diagnosis by itself.

A pathologist examines the sample under a microscope and determines whether malignant epithelial cells are present. The report may also identify the carcinoma subtype, grade, invasion pattern, lymphovascular involvement and other relevant features.

Additional tests may then examine proteins, receptors, gene mutations or other biomarkers.

The typical diagnostic process may include:

• Clinical examination and review of symptoms

• Imaging such as ultrasound, CT, MRI or other organ-specific studies

• Biopsy or surgical tissue sampling

• Histopathologic examination

• Immunohistochemistry when the cell origin is uncertain

• Molecular or biomarker testing when it may affect treatment

• Staging investigations when invasive cancer has been confirmed

Not every person needs every test. The investigation depends on where the tumor is located and what the initial pathology shows.

What Do Grade and Stage Mean in Carcinoma?

Grade describes how abnormal the cancer cells appear under the microscope, while stage describes how far the cancer has spread anatomically.

They answer different questions.

Tumor grade can provide information about differentiation. Well-differentiated cancer cells retain more characteristics of the original tissue, while poorly differentiated cells may look much less like normal tissue. The meaning and grading system vary by cancer type.

Stage usually incorporates information about the primary tumor, regional lymph nodes and distant metastases, although specific staging systems differ.

Two people can therefore have the same carcinoma subtype but very different stages.

A small localized carcinoma and the same histologic cancer after distant spread should not be treated as equivalent conditions. Stage is one of the major factors used when selecting therapy and estimating prognosis.

Can Carcinoma Spread to Other Parts of the Body?

Yes, invasive carcinomas can metastasize when cancer cells leave the primary tumor and establish new tumors elsewhere.

Spread can occur through lymphatic channels, blood vessels or direct invasion into surrounding structures.

The organs most likely to receive metastases depend partly on where the original cancer began.

Importantly, metastatic cancer keeps the identity of its primary cancer. If colon adenocarcinoma spreads to the liver, it remains metastatic colon adenocarcinoma rather than becoming primary liver cancer.

Pathologists can sometimes use cell appearance, immunohistochemistry and molecular tests to help determine the original site when a metastatic tumor is discovered before the primary cancer is known.

In a small proportion of patients, the primary site remains unidentified despite investigation. This situation is known as carcinoma of unknown primary.

How Is Carcinoma Treated?

Carcinoma treatment depends on the organ of origin, histologic subtype, stage, biomarkers and the patient's overall medical condition.

There is no universal carcinoma treatment.

Surgery can be used to remove localized tumors when complete resection is feasible. Radiation therapy can treat a defined area and may be used alone or before or after surgery.

Chemotherapy uses systemic drugs to kill or slow rapidly dividing cancer cells and remains important for many carcinomas.

Targeted therapy acts on particular molecular changes or proteins that contribute to cancer growth. These treatments are usually useful only when the tumor contains the relevant target.

Immunotherapy helps the immune system recognize or attack cancer more effectively and has become an important treatment for selected lung, skin, bladder, kidney, head and neck and other cancers.

Hormone therapy is particularly important in carcinomas whose growth depends on hormonal signaling, including selected breast and prostate cancers.

Many patients receive more than one treatment. Surgery may be followed by chemotherapy, radiation or systemic therapy, while advanced disease may be treated primarily with medications.

How Do Biomarkers Affect Carcinoma Treatment?

Biomarkers can identify biological features of a carcinoma that help determine whether particular treatments are likely to work.

Modern oncology increasingly classifies cancers according to molecular characteristics in addition to organ and histology.

A lung adenocarcinoma, for example, may undergo testing for molecular alterations that have corresponding targeted treatments. Breast carcinoma may be evaluated for hormone receptors and HER2 status.

Other cancers may be tested for features that help predict whether immunotherapy or a specific targeted drug could be useful.

A treatment that works well for a tumor with one molecular alteration may provide little benefit when that target is absent.

For this reason, two patients with the same broad carcinoma type can sometimes receive very different treatment plans.

Biomarker testing is therefore an increasingly important bridge between pathology and treatment selection.

Is Carcinoma Curable?

Some carcinomas can be cured, particularly when they are detected while localized and can be completely treated, but carcinoma as a whole does not have one cure rate.

Outcome depends on the exact cancer.

A small basal cell carcinoma of the skin has a very different outlook from metastatic pancreatic adenocarcinoma, even though both are carcinomas.

The organ of origin, subtype, stage, grade, molecular profile, response to treatment and overall health all influence prognosis.

Even stage alone does not tell the complete story because modern targeted and immune therapies have changed outcomes for selected molecular subgroups.

For this reason, generalized questions such as what is the survival rate for carcinoma have no medically meaningful single answer.

The pathology diagnosis and stage must first be specified.

Does a Carcinoma Diagnosis Always Mean the Cancer Is Advanced?

No, carcinoma does not mean that cancer is advanced or metastatic.

The word describes the cellular origin of the cancer, not its stage.

A carcinoma can range from carcinoma in situ to a small localized invasive tumor or widely metastatic disease.

This distinction is especially important when someone first sees the term carcinoma in a pathology report. The presence of the word itself does not reveal the prognosis.

The next questions should be where the carcinoma started, what subtype it is, whether it is invasive and what stage has been established.

Those details provide far more useful information than the broad label alone.

What Information Should You Look for After a Carcinoma Diagnosis?

After a carcinoma diagnosis, the most useful information is the complete pathology and staging description rather than simply the word carcinoma.

A patient should try to understand the primary site, histologic subtype, grade and whether the cancer has invaded surrounding tissue.

The stage should then clarify whether lymph nodes or distant organs are involved.

Biomarker testing may further define treatment options in cancers where actionable molecular characteristics are relevant.

A practical way to clarify a diagnosis is to ask the oncology team to state it in one complete sentence. For example, that sentence might include the organ, histologic subtype, stage and major treatment-relevant biomarkers.

Once those details are known, treatment choices and prognosis can be discussed much more accurately.

What Is the Most Important Thing to Understand About Carcinoma?

The most important point is that carcinoma is a broad cancer category rather than one specific disease.

Its meaning becomes clinically useful only when combined with the organ where it started, the exact epithelial subtype, whether it is invasive, its stage and any relevant biomarkers.

This is why two people who have both been told they have carcinoma may receive completely different treatments and have very different expected outcomes.

The word carcinoma establishes the cancer's general cellular family. The complete pathology and staging information establish what that diagnosis means for the individual patient.